Post Transplant Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00395902
Recruitment Status : Completed
First Posted : November 6, 2006
Last Update Posted : December 28, 2007
Information provided by:

Brief Summary:
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Condition or disease Intervention/treatment
Kidney Tansplant Secondary Hyperparathyroidism Hyperparathyroidism Drug: Sensipar after Post Transplant

Study Type : Observational
Estimated Enrollment : 50 participants
Time Perspective: Retrospective
Official Title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients
Study Start Date : August 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Adults >= 18 years old
  • Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

  • Subjects who received Sensipar before undergoing a kidney transplant
  • Subjects receiving dialysis post-transplant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00395902

Sponsors and Collaborators
Study Director: MD Amgen

Additional Information:
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00395902     History of Changes
Other Study ID Numbers: 20040261
First Posted: November 6, 2006    Key Record Dates
Last Update Posted: December 28, 2007
Last Verified: December 2007

Keywords provided by Amgen:

Additional relevant MeSH terms:
Hyperparathyroidism, Secondary
Parathyroid Diseases
Endocrine System Diseases
Cinacalcet Hydrochloride
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs